PureTech Health (NASDAQ:PRTC) Shares Gap Down to $25.78

PureTech Health plc (NASDAQ:PRTCGet Rating) gapped down prior to trading on Thursday . The stock had previously closed at $25.78, but opened at $23.52. PureTech Health shares last traded at $23.52, with a volume of 5 shares changing hands.

Analyst Upgrades and Downgrades

PRTC has been the topic of several research reports. Piper Sandler set a $37.00 price target on PureTech Health in a report on Monday, June 20th. SVB Leerink dropped their price target on PureTech Health from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday, June 15th.

PureTech Health Stock Performance

The firm’s 50 day simple moving average is $22.42 and its 200-day simple moving average is $26.32. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.22 and a current ratio of 2.22.

About PureTech Health

(Get Rating)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.

Read More

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.